Axogen Inc Quick Ratio (AXGN) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Axogen inc   (NASDAQ: AXGN)

Axogen Inc 's Quick Ratio

AXGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Axogen Inc 's Cash & cash equivalent grew by 212.42 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Axogen Inc 's Quick Ratio to 9.55, above Axogen inc average Quick Ratio.

Within Medical Equipment & Supplies industry 48 other companies have achieved higher Quick Ratio than Axogen Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 772 to 973.

Explain Quick Ratio?
How much Cash & cash equivalents AXGN´s has?
What are AXGN´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AXGN/financial-strength
https://api.csimarket.com/api/v1/companies/AXGN/fundamentals
https://api.csimarket.com/api/v1/companies/AXGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
AXGN Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 42.01 %
Y / Y Cash & cash equivalent Change 872.5 %
Quick Ratio MRQ 9.55
AXGN's Total Ranking # 973
Seq. Current Liabilities Change 20.02 %
Seq. Cash & cash equivalent Change 212.42 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 49
Healthcare Sector # 361
Overall Market # 973


Quick Ratio Statistics
High Average Low
17.15 4.39 0.46
(Sep 30 2013)   (Dec 31 2010)




Financial Statements
Axogen Inc 's Current Liabilities $ 36 Millions Visit AXGN's Balance sheet
Axogen Inc 's Cash & cash equivalent $ 348 Millions Visit AXGN's Balance sheet
Source of AXGN's Sales Visit AXGN's Sales by Geography


Cumulative Axogen Inc 's Quick Ratio

AXGN's Quick Ratio for the trailling 12 Months

AXGN Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 15.68 %
Y / Y Cash & cash equivalent TTM Growth 396.94 %
Quick Ratio TTM 5.38
Total Ranking TTM # 3799
Seq. Current Liabilities TTM Growth 10.66 %
Seq. Cash & cash equivalent TTM Growth 107.56 %


On the trailing twelve months basis AXGN Cash & cash equivalent more than doubled by 872.5 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Axogen Inc 's Quick Ratio to 5.38, above AXGN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 197 other companies have achieved higher Quick Ratio than Axogen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2819 to 3799.

Explain Quick Ratio?
How much Cash & cash equivalents AXGN´s has?
What are AXGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 198
Healthcare Sector # 878
Within the Market # 3799


trailing twelve months Quick Ratio Statistics
High Average Low
9.84 3.2 0.53
(Mar 31 2014)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Bone Biologics Corporation  12.66 $ 6.088  Millions$ 0.481  Millions
Vivos Inc  11.65 $ 1.807  Millions$ 0.155  Millions
Anteris Technologies Global Corp   11.37 $ 216.987  Millions$ 19.085  Millions
Lemaitre Vascular Inc   11.26 $ 389.721  Millions$ 34.620  Millions
Mobia Medical Inc   10.63 $ 160.692  Millions$ 15.115  Millions
Axogen inc   9.55 $ 348.068  Millions$ 36.456  Millions
Delcath Systems Inc   8.01 $ 104.315  Millions$ 13.022  Millions
Orchestra Biomed Holdings Inc   7.16 $ 101.907  Millions$ 14.228  Millions
Envveno Medical Corporation  7.13 $ 18.472  Millions$ 2.589  Millions
Ceribell Inc   6.51 $ 117.467  Millions$ 18.034  Millions
Autonomix Medical Inc   6.13 $ 7.692  Millions$ 1.254  Millions
Iradimed Corporation  6.13 $ 63.288  Millions$ 10.323  Millions
Orasure Technologies Inc  5.90 $ 148.238  Millions$ 25.104  Millions
Perspective Therapeutics Inc   5.09 $ 201.695  Millions$ 39.602  Millions
Clearpoint Neuro Inc   4.68 $ 46.184  Millions$ 9.869  Millions
Cvrx inc   4.67 $ 58.746  Millions$ 12.583  Millions
Dexcom Inc   4.25 $ 964.800  Millions$ 227.000  Millions
Innovative Eyewear Inc   3.86 $ 3.197  Millions$ 0.829  Millions
Sight Sciences Inc   3.84 $ 77.402  Millions$ 20.137  Millions
Alpha Pro Tech Ltd   3.78 $ 25.546  Millions$ 6.750  Millions
Hyperfine Inc   3.60 $ 37.872  Millions$ 10.532  Millions
Profound Medical Corp   3.41 $ 33.343  Millions$ 9.771  Millions
Rxsight Inc   3.40 $ 254.683  Millions$ 74.952  Millions
Omada Health Inc   3.23 $ 243.151  Millions$ 75.379  Millions
Transmedics Group Inc   3.22 $ 492.962  Millions$ 152.857  Millions
Trisalus Life Sciences Inc   3.15 $ 41.057  Millions$ 13.014  Millions
Procept Biorobotics Corporation  3.10 $ 218.369  Millions$ 70.353  Millions
Carlsmed Inc   3.08 $ 56.207  Millions$ 18.237  Millions
Neuropace Inc   3.08 $ 49.431  Millions$ 16.070  Millions
Outset Medical Inc   3.07 $ 136.627  Millions$ 44.453  Millions

Date modified: 2026-10-29T17:22:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.